An industry expert shares how emerging micro and nanotechnologies could shape the next generation of implantable drug-delivery systems.
Implants - Industry Insight
The market for minimally invasive glaucoma surgery devices is expected to pop for the foreseeable future.
Cardiology societies recently updated guidelines on the management of adults at risk for sudden cardiac death to include the use of a subcutaneous implantable cardioverter-defibrillator (S-ICD). But are the latest recommendations having unintended consequences?
Robotics, pricing concerns, and the prevalence of more procedures being performed at ambulatory centers are some of the hot topics in the orthopedics market.
Spinal implant manufacturers have to be able to spot gaps where products are underutilized and need evidence-supported arguments along with value propositions to be successful in the market place.
Len Czuba, president of Czuba Enterprises, shares tips about developing implantable devices, and the keys to sourcing the best materials without spending a fortune.
Edwards Lifesciences, part of the lead pack of companies racing toward a transcatheter mitral valve replacement, announced it has paused its trials for its CardiAQ transcatheter mitral program.
InspireMD is building a stent product portfolio around its MicroNet technology, aimed at preventing embolization.
Boston Scientific's chief medical officer discusses Watchman, Lotus Edge, and the company's three-pronged bet on bioresorbable scaffold technology.
There is still hope for device-based treatments for drug-resistant hypertension. Here, a few of the approaches being pursued and the lessons learned from the last round of development.
Want to learn more about transcatheter mitral valve replacement technology before it become mainstream? Two experts offer an introduction to the TMVR market opportunity.
The Alphabet subsidiary is partnering with a UK hospital to test whether its algorithm can help diagnose diabetic retinopathy and age-related macular degeneration sooner.